Giordano Christopher Thomas
Giordano Christopher Thomas, CEO, reported an open-market or private purchase at TENAX THERAPEUTICS, INC. involving 4850.000000 shares for an estimated $8837.19. Reported holdings after the transaction were 22174.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
- Trade date
- Sep 15, 2026
- Filing date
- Sep 16, 2026
How reported position traded is calculated
Shares purchased ÷ (holdings after − shares purchased). Estimated position before: 17,324 shares.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
TENX price since this filing
Daily closing prices, with the filing date and available return windowsTransaction facts
Stored Form 4 columns with their raw values
- Type
- Buy Code P
- Identifier
- 0001871714-26-000002 Common Stock
- Transaction date
- Sep 15, 2026 Filed Sep 16, 2026, 01:38 AM · 1d delay
- Shares
- 4,850 sh $1.82 per share
- Estimated value
- $8.83k Computed from shares × price
- Holdings after
- 22,174 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
+48 points
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a high positive filing-only score. It may deserve closer research, but it is not an investment recommendation.
How this score is calculated
- open_market_purchase+12 points
transaction_code = P
Code P is a discretionary open-market purchase. - direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake. - ceo_buy+12 points
is_officer + officer_title/role mentions CEO
CEO open-market purchase. - cluster_buy+14 points
cluster-buy signal matched
Multiple insiders bought within the configured window. - timely_filing+4 points
reporting_delay_days = 1
Filing reported within two business days of the transaction.
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
CEO
- F1
This transaction was executed in multiple trades at prices ranging from $1.87 to $1.88. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide up…
- F2
This transaction was executed in multiple trades at prices ranging from $1.82 to $1.83. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide up…
- F3
The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on January 9, 2027, and thereafter 1/36th of the remaining shares will vest…
- F4
The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on May 16, 2026, and thereafter 1/36th of the remaining shares will vest on…
- F5
The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of May 17, 2025, May 17, 2026, May 17, 2027, and May 17, 2028, subj…
- F6
The options vested and became exercisable as follows: 25% of the underlying shares of common stock vested and became exercisable on each of June 9, 2023, June 9, 2024, June 9, 2025, and June 9, 2026,…
- F7
The options vested and became exercisable as follows: 25% of the underlying shares of common stock vested and became exercisable on each of July 6, 2022, July 6, 2023, July 6, 2024, and July 6, 2025,…
0 other transactions
0 recent txs